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Objectives This study sought to assess the safety and efficacy of paclitaxel-coated balloon (PCB) angioplasty in an interna-
tional, multicenter, prospective, large-scale registry study.
Background In small randomized trials, PCB angioplasty was superior to uncoated balloon angioplasty for treatment of bare-
metal stent (BMS) and drug-eluting stent (DES) restenosis.
Methods Patients treated with SeQuent Please PCBs were included. The primary outcome measure was the clinically
driven target lesion revascularization (TLR) rate at 9 months.
Results At 75 centers, 2,095 patients with 2,234 lesions were included. The TLR rate was 5.2% after 9.4 months.
Definite vessel thrombosis occurred in 0.1%. PCB angioplasty was performed in 1,523 patients (72.7%)
with DES or BMS restenosis and 572 patients (27.3%) with de novo lesions. The TLR rate was significantly
lower in patients with PCB angioplasty for BMS restenosis compared with DES restenosis (3.8% vs. 9.6%,
p  0.001). The TLR rate did not differ for PCB angioplasty of paclitaxel-eluting stent and non–paclitaxel-
eluting sten restenosis (8.3% vs. 10.8%, p  0.46). In de novo lesions (small vessels), the TLR rate was
low and did not differ between PCB angioplasty with and without additional BMS implantation
(p  0.31).
Conclusions PCB angioplasty in an all-comers, prospective, multicenter registry was safe and confirmed in a large population
the low TLR rates seen in randomized clinical trials. PCB angioplasty was more effective in BMS restenosis com-
pared with DES restenosis, with no difference regarding the type of DES. (J Am Coll Cardiol 2012;60:1733–8)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.040In randomized clinical trials, paclitaxel-coated balloon
angioplasty (PCB) was superior to uncoated balloon
angioplasty for the treatment of in-stent restenosis (ISR)
in bare-metal stents (BMS) (1) as well as for the
treatment of ISR in drug-eluting stents (DES) (2,3). For
de novo coronary artery disease, the combination of a
PCB plus an endothelial progenitor cell– capturing stent
was superior regarding angiographic and clinical outcome
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stent alone (4). Furthermore, in small coronary arteries,
PCB therapy without additional stent implantation has
been associated with favorable results (5). The effect of
PCB therapy for ISR was maintained in long-term
follow-up (6). However, these studies were limited by moder-
ate numbers of patients ranging from 50 to 131. Therefore, we
performed the SeQuent Please World Wide Registry to demon-
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ment with the SeQuent Please PCB
(B. Braun, Melsungen, Germany) in
routine real-world practice.
Methods
Patient population. The aim of
this multicenter, international,
all-comers registry study was to
assess the safety and efficacy of
PCB therapy in a large popula-
tion with real-world treatment.
Patients treated with the Se-
Quent Please PCB were in-
cluded at 75 sites from 8 coun-
tries. Patients received 500 mg of
aspirin before the intervention or
were receiving long-term treat-
ment. A clopidogrel loading dose of 600 mg was adminis-
tered. Dual-antiplatelet therapy was recommended for at least
1 month. Patients with contraindications to dual-antiplatelet
therapy, women with childbearing potential, and patients with
contraindications or known hypersensitivity to acetylsalicylic acid,
clopidogrel, paclitaxel, or heparin were not included. The protocol
was ethically approved. All patients gave written informed con-
sent. Data were captured using a common electronic case report
form.
Study procedure. The PCB catheter was loaded with pacli-
taxel 3 g/mm2. The length of the PCB catheter was chosen
to exceed the target lesion for at least 2 to 3 mm. PCBs were
inflated for 30 to 60 s with a minimum of 10 bar. BMS were
implanted if the result after PCB therapy alone was not
satisfactory because of recoil, residual stenosis, or dissections.
In case of stent implantation outside the PCB-treated seg-
ment, another PCB was inflated to fully cover the stented
segment with a PCB. Lesion length and vessel reference
diameter were assessed using online quantitative coronary
angiography or visual estimation.
Primary outcome measures. The primary endpoint was
the clinically driven target lesion revascularization (TLR)
rate at 9 months. The secondary endpoint was the rate of
major adverse cardiac events (MACEs), defined as a com-
posite of cardiac death, myocardial infarction, and TLR.
Patients were followed by telephone or hospital visit at 9
months and will undergo 24-month follow-up. Further-
more, definite vessel thrombosis was defined in analogy to
the Academic Research Consortium criteria for definite
stent thrombosis (7).
Statistical analysis. Continuous variables are presented as
mean (range)  SD. Discrete variables are expressed as
counts and percents. Categorical variables were compared
using Pearson’s chi-square test. Differences between pro-
portions and t tests were computed using SPSS version 18.0
(SPSS, Inc., Chicago, Illinois). Time-to-event data are
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
ISR  in-stent restenosis
MACE  major adverse
cardiac event(s)
PCB  paclitaxel-coated
balloon
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationshown as Kaplan-Meier curves and were compared usinglog-rank tests. Multivariate regression analysis was performed
to evaluate risk factors for the need for TLR after treatment of
ISR and of de novo lesions. The following variables were
included in both models: gender, diabetes mellitus, acute
coronary syndromes, ostial lesion, and lesion location in a
native vessel versus a graft vessel. Furthermore, BMS restenosis
versus DES restenosis was included in ISR analysis and PCB
versus PCB plus BMS in de novo lesion analysis.
Results
Total population. Between February 2008 and Novem-
ber 2011, a total of 2,095 patients with 2,234 lesions were
included. Seven hundred fifty-four patients had diabetes
mellitus (36.0%), 1,561 had hyperlipidemia (74.5%),
1,795 had arterial hypertension (85.7%), 872 had histo-
ries of smoking (41.6%), 132 required dialysis (6.3%),
and 1,552 were men (74.1%). PCB angioplasty was
performed predominantly for the treatment of ISR (n 
1,523 [72.7%]). Treatment of de novo coronary artery
disease was done in 572 patients (27.3%). For the total
population, the target lesion was located in the left
anterior descending coronary artery in 41.3%, the circum-
flex coronary artery in 24.6%, the right coronary artery in
29.1%, and grafts in 5.0%. The mean lesion length was
17.3  8.0 mm, and the mean reference vessel diameter
was 2.9  0.5 mm.
For treatment of 2,234 lesions, a total of 2,347 PCBs
were used (1.1 PCBs per lesion). The mean length of PCBs
was 20.3  5.5 mm, with a mean diameter of 2.9  0.4
mm. The mean inflation pressure was 12.9  3.8 bar. After
PCB angioplasty, dissections were documented in 4.7%
(n  104), requiring additional stent implantation in 82 of
these cases.
Clinical follow-up was obtained after 9.4  2.3
months. The primary outcome measure, TLR, was ob-
served in 5.2% of the total population. MACEs occurred
in 6.7% and were a composite of cardiac death in 1.8%
and myocardial infarction in 0.8% plus TLR. The target
vessel revascularization (TVR) rate was 6.2%. Throm-
botic events at the target lesion occurred in 0.1% of the
total population (n  2).
ISR: BMS versus DES. In 1,207 patients with 1,264
ISR lesions, the type of restenosed stent was documented.
PCB angioplasty was performed in 743 patients with 782
BMS restenoses and in 464 patients with 482 DES
restenoses. The frequency of cardiovascular risk factors
was similar between groups except for a significantly
higher rate of arterial hypertension in patients with BMS
restenosis (Table 1). Baseline lesion characteristics and
procedural data did not differ except for a higher rate of
graft and ostial lesions and a lower rate of American
Heart Association/American College of Cardiology type
B/C lesions in DES restenosis compared with BMS
restenosis (Table 2). The length of the PCB treated
segment was 3 to 4 mm longer compared with the lesion
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success was high, ranging between 98.3% and 99.3%.
The primary outcome measure, TLR, was significantly
lower in BMS restenosis compared with DES restenosis
(3.8% vs. 9.6%, p  0.001) (Fig. 1). Acute coronary
yndromes (p  0.034), ostial lesions (p  0.023), graft
esions (p  0.004), and DES restenosis (p  0.001) were
ignificant risk factors for TLR. Furthermore, the frequency
f MACEs was significantly lower for BMS restenosis
ompared with DES restenosis (Figs. 1 and 2). There were
definite vessel thromboses, 1 in each group, resulting in vessel
hrombosis rates of 0.2% for DES restenosis and 0.1% for
MS restenosis (p  0.75). The vessel thrombosis in DES
SR occurred 169 days after PCB treatment in a segment with
revious brachytherapy. The vessel thrombosis in BMS ISR
ccurred 53 days after PCB angioplasty, after stopping dual-
ntiplatelet therapy for a surgical procedure.
In 389 patients, the type of restenosed DES was docu-
ented. There were 129 patients with paclitaxel-eluting stent
PES) restenosis and 260 patients with non-PES restenosis.
aseline and procedural data did not differ between both
roups except for higher frequencies of arterial hypertension in
ES restenosis (90.9% vs. 81.6%, p  0.02) and total occlu-
ions (10.1% vs. 4.2%, p  0.024) compared with non-PES
estenosis. There were no differences for PCB treatment of
ES restenosis compared with non-PES restenosis with re-
pect to MACEs, TLR, TVR, myocardial infarction, or
ardiac death (Fig. 3).
e novo lesions. There were 491 patients with de novo
esions and treatment with PCBs alone (n  390) or PCBs
lus BMS (n  101). Baseline and procedural data for
atients with PCBs versus PCBs plus BMS were almost
imilar (Tables 3 and 4). Lesions were located in small
essels, demonstrated by a mean reference diameter of 2.6
.5 mm. Rates of MACEs, TLR, and TVR were low and
id not differ in patients with versus without additional
tent implantation (Fig. 4). Female sex (p  0.043) and the
resence of diabetes mellitus (p  0.023) were significant
Baseline Data: In-Stent RestenosisTable 1 Baseline Data: In-Stent Restenosis
Variable
DES
Restenosis
BMS
Restenosis p Value
Number of patients 464 743 —
Number of lesions 482 782 —
Men 71.3% (331) 74.3% (552) 0.26
Cardiac risk factors
Diabetes mellitus 37.5% (174) 35.3% (262) 0.43
Arterial hypertension 85.6% (397) 89.8% (667) 0.027
Hyperlipidemia 84.1% (390) 79.9% (594) 0.07
History of smoking 42.9% (199) 47.2% (351) 0.13
Dialysis 8.4% (39) 7.9% (59) 0.77
Acute coronary syndromes 13.8% (64) 14.7% (109) 0.67
BMS  bare-metal stent(s); DES  drug-eluting stent(s).redictors for TLR.
c
Riscussion
he main finding of the prospective, multicenter, all-
omers SeQuent Please World Wide Registry was that
reatment with PCBs in a real-world setting including a
arge population with more than 2,000 patients was safe
nd resulted in a low rate of clinically driven TLR. PCB
ngioplasty in BMS restenosis resulted in a significantly
ower TLR rate compared with PCB angioplasty for DES
estenosis, with no difference regarding the type of DES.
or de novo lesions in small vessels, the TLR rate was
ow both for treatment with PCB alone and with BMS.
In the SeQuent Please World Wide Registry, PCB
ngioplasty was predominantly used for the treatment of
estenosis in BMS or DES. Over 9 months of clinical
ollow-up, the TLR and MACE rates were low, at 5.2%
nd 6.7%, respectively. Furthermore, the frequency of vessel
hrombosis was only 0.1% in ISR.
Randomized trials have shown that PCB angioplasty is
uperior to uncoated balloon angioplasty for the treat-
ent of BMS restenosis and DES restenosis (1–3). In
hese trials with angiographic follow-up, the need for
LR after PCB angioplasty was 0% for 26 patients with
MS restenosis within 12-month follow-up (1) and 4%
n 54 patients with BMS restenosis within 12 months (7),
ompared with 4.3% in 25 patients with sirolimus-eluting
tent (SES) restenosis within 6 months (2) and 15.3% in
2 patients with DES restenosis (3). In the SeQuent
lease World Wide Registry, the TLR rate was signifi-
antly higher in patients with DES restenosis compared
Lesion Characteristics: In-Stent RestenosisTable 2 Lesion Characteristics: In-Stent Restenosis
Characteristic
DES
Restenosis
BMS
Restenosis p Value
Number of lesions 482 782
Target vessel 0.004
LAD 37.7% 41.1%
CX 20.8% 22.9%
RCA 32.6% 32.0%
Graft 8.8% 4.0%
Total occlusion 5.6% (27) 6.9% (54) 0.36
Intracoronary thrombus 2.9% (14) 1.8% (14) 0.19
Diffuse vessel disease 54.6% (263) 53.7% (420) 0.77
Ostial lesion 16.6% (80) 10.7% (84) 0.003
AHA/ACC type B2/C lesion 41.8% (183) 49.4% (296) 0.02
Lesion length (mm) 17.1 8.9 17.5 7.9 0.50
Reference diameter (mm) 3.0 0.5 3.0 0.5 0.71
Number of PCBs used 508 836
Technical success 98.3% 99.3% 0.39
PCB diameter (mm) 3.0 0.4 3.0 0.4 0.30
Length of PCB (mm) 20.7 5.7 21.3 5.5 0.07
Inflation pressure (bar) 13.7 4.0 13.4 3.7 0.19
Dissection 2.2% (11) 3.5% (29) 0.17
With additional stenting 63.6% (7) 89.7% (26) 0.05
Values are n, %, % (n), or mean  SD.
ACC  American College of Cardiology; AHA  American Heart Association; CX  circumflexoronary artery; LAD  left anterior descending coronary artery; PCB  paclitaxel-coated balloon;
CA right coronary artery; other abbreviations as in Table 1.
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SeQuent Please World Wide Registry October 30, 2012:1733–8with BMS restenosis. DES restenosis was an indepen-
dent risk factor for TLR. This may be explained by
higher late loss after treatment of DES restenosis com-
pared with BMS restenosis. This is probably triggered by
11.6
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MACE TLR
DES-IS%
p<0.001 p<0.001
Figure 1 PCB Treatment for ISR: Clinical Events
Major adverse cardiac events (MACE), target lesion revascularization (TLR), target
more frequently in patients with paclitaxel-coated balloon (PCB) treatment for drug
during 9-month follow-up.
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Figure 2 Kaplan-Meier Survival Curves
for DES ISR Versus BMS ISR
Kaplan-Meier survival curves regarding major adverse cardiac events (MACE)
demonstrate a significant lower risk for MACE with paclitaxel-coated balloon
treatment for drug-eluting stent (DES) in-stent restenosis (ISR) compared with
bare-metal stent (BMS) ISR.the use of DES for lesions with a high risk for restenosis,
while lesions with a low risk for restenosis are treated
with BMS. In randomized trials with angiographic
follow-up, mean late luminal loss with PCB angioplasty
was 0.03  0.48 mm for BMS restenosis (1), 0.18  0.45
m for SES restenosis (2), and 0.43  0.61 mm for DES
estenosis (3). Another possible explanation might be
that in DES restenosis, there was already a failure of local
antiproliferative drug therapy, whereas BMS restenosis is
still naive regarding antiproliferative drug treatment.
This is supported by our data showing no difference in
TLR with PCB for PES and non-PES restenosis. Fur-
thermore, this effect seems to be similar with DES. In the
Intracoronary Stenting and Angiographic Results: Drug-
Eluting Stents for In-Stent Restenosis I trial (8), patients
with BMS restenosis were randomized to uncoated bal-
loon angioplasty and PES or SES implantation. The
TVR rate differed significantly, at 33%, 19%, and 8%,
respectively, and was higher than our 5.2% TVR rate in
the SeQuent Please World Wide Registry using PCB
angioplasty. In the Intracoronary Stenting and Angio-
graphic Results: Drug-Eluting Stents for In-Stent Reste-
nosis II trial (9), patients with SES restenosis were
randomized to treatment with PES or SES. Late luminal
loss for treatment with DES was clearly higher in DES
restenosis (0.38 mm for PES, 0.40 mm for SES) (9)
compared with BMS restenosis (0.26 mm for PES, 0.10
mm for SES) (8).
In a small registry, PCB angioplasty for de novo lesions in
3.2
0.7
5.2
1.2 1.1
MI Cardiac Death
BMS-ISR
02 p=0.029 p=0.566
l revascularization (TVR), and myocardial infarction (MI) occurred significantly
g stent (DES) in-stent restenosis (ISR) compared with bare-metal stent (BMS) ISR10.1
TVR
R
p=0.0
vesse
-elutinsmall coronary arteries was associated with a TLR rate of
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October 30, 2012:1733–8 SeQuent Please World Wide Registry12% within 12 months (5). We now demonstrate in more
than 400 patients with de novo lesions that PCB angioplasty
with or without BMS was safe and associated with low TLR
rates (1.0% and 2.4% at 9 months). Diabetes mellitus was a
significant predictor for TLR.
Study limitations. This was a prospective, large-scale registry
adding important new insight into PCB therapy to the moder-
ately sized randomized trials. Therefore, comparison of subgroups
is only hypothesis generating and needs to be further evaluated.
There was no angiographic core lab. Therefore, the frequency and
impact of geographic miss cannot be reported.
Conclusions
PCB angioplasty in an all-comers, prospective, multicenter
registry was safe and confirmed in a large population the low
11.7
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p=0.810 p=0.460
Figure 3 PCB Treatment for PES ISR and non-PES ISR: Clinical
The occurrence of major adverse cardiac events (MACE), target lesion revasculariz
diac death did not differ with paclitaxel-coated balloon (PCB) treatment for paclitax
9-month follow-up.
Baseline Data: De Novo LesionsTable 3 Baseline Data: De Novo Lesions
Variable PCB Alone PCB and BMS p Value
Number of patients 390 101 —
Number of lesions 453 106 —
Men 76.4% (298) 80.2% (81) 0.42
Cardiac risk factors
Diabetes mellitus 34.6% (135) 30.7% (31) 0.45
Arterial hypertension 85.1% (331) 76.2% (77) 0.034
Hyperlipidemia 71.5% (278) 69.3% (70) 0.67
History of smoking 38.3% (149) 42.6% (43) 0.43
Dialysis 3.9% (15) 3.0% (3) 0.67
Acute coronary syndromes 24.4% (59) 22.8% (23) 0.74Abbreviations as in Tables 1 and 2.TLR rates seen in randomized clinical trials. PCB angio-
plasty was more effective in BMS restenosis compared with
DES restenosis, with no difference regarding the type of
DES.
2.5
0.8
1.3
3.9
0.9
MI Cardiac Death
n-PES-ISR
46 p=0.490 p=0.972
ts
TLR), target vessel revascularization (TVR), myocardial infarction (MI), and car-
ing stent (PES) in-stent restenosis (ISR) compared with non-PES ISR during
Lesion Characteristics: De Novo LesionsTable 4 Lesion Characteristics: De Novo Lesions
Characteristic PCB Alone PCB and BMS p Value
Number of lesions 453 106
Target vessel 0.45
LAD 42.1% 50.0%
CX 33.5% 26.4%
RCA 20.0% 18.9%
Graft 4.4% 4.7%
Total occlusion 9.1% (41) 6.6% (7) 0.42
Intracoronary thrombus 4.4% (20) 5.7% (6) 0.58
Diffuse vessel disease 46.1% (209) 36.8% (39) 0.08
Ostial lesion 15.7% (12) 16.0% (17) 0.93
AHA/ACC type B2/C lesion 41.0% (105) 59.0% (46) 0.005
Lesion length (mm) 14.9 5.7 18.9 9.5 0.001
Reference diameter (mm) 2.5 0.5 2.8 0.5 0.001
Number of PCBs used 470 109
Technical success 96.9% 97.1% 0.75
PCB diameter (mm) 2.5 0.4 2.7 0.4 0.001
Length of PCB balloon (mm) 18.5 5.1 21.0 6.2 0.001
Inflation pressure (bar) 11.5 3.2 10.8 3.3 0.04
Dissection 3.4% (13) 24.8% (25) 0.28
With additional stenting 0% 100%9.2
1
TVR
no
p=0.5
Even
ation (
el-elutValues are n, %, % (n), or mean  SD.
Abbreviations as in Tables 1 and 2.
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